HomeDealsNegotiationsPolicyPipelineMoneyPeopleDataThe WeekPharmTech 100Deal TrackerResearch

Results Show Giving Prophylactic Tocilizumab Reduces CRS in Outpatient Delivery of Teclistamab, Talquetamab

Results Show Giving Prophylactic Tocilizumab Reduces CRS in Outpatient Delivery of Teclistamab, Talquetamab

By AJMC · Jun 2, 2026 · via AJMC

This is an aggregated industry headline. Read the full story at AJMC

Tags
theweekformat:headlineheadlineAJMC
The Insider - Weekly pharma intelligence
Deals, negotiations, and policy analysis. Delivered when it matters.
No sponsored content. No noise. Unsubscribe anytime.
More from The Week
All The Week →
Eisai whips up Alzheimer's dietary guidance to expand nutrition program beyond cancer
The WeekFiercePharma ↗
Eisai has partnered with CaringKind to expand its nutrition support initiative to cover Alzheimer's disease an…
Jun 2, 2026
Praxis pauses one of its seizure programs after phase 2 fail
The WeekFierceBiotech ↗
Praxis Precision Medicines' epilepsy pipeline has suffered a setback after a next-gen NaV blocker failed to su…
Jun 2, 2026
Abivax’s Phase 3 Triumph Turns Risk Event as Cancer Cases Emerge
The WeekBriefing
Obefazimod delivered industry-leading remission rates in ulcerative colitis, but new cancer cases wiped out th…
Jun 2, 2026